Liver Disease
Conference Coverage
FIB-4 could ID liver risk in primary care
The Fibrosis-4 index is most often used in specialty clinics, but showed promise in primary care.
Conference Coverage
Bulevirtide shows real-world efficacy versus HDV
French program reveals good cure rates, but also a high rate of modifications or discontinuations.
From the AGA Journals
COVID-19 vaccines: Lower serologic response among IBD, rheumatic diseases
Patients with immune-mediated inflammatory diseases urged to get full mRNA vaccine series without delay and possibly a third dose.
From the AGA Journals
Human CRP protects against acetaminophen-induced liver injury in mice
NAC is effective during only the early phases of the acetaminophen-induced liver injury, whereas human CRP was still highly effective in this...
From the Journals
Virtual center boosts liver transplant listings in rural area
By tackling pretransplant screening, a medical center in New Hampshire expedited listing for rural residents.
Conference Coverage
NAFLD, ALD prevalent among teens, young adults
It’s important to “mitigate modifiable risk factors to prevent disease development and disease progression to potentially advanced fibrosis and...
Conference Coverage
Be cautious with HBV drug withdrawal
Severe flares can follow in the long term after withdrawal of nucleoside/nucleotide analogues.
Conference Coverage
Cirrhosis comorbidities tied to worse outcomes
Compensated cirrhosis patients with three comorbidities may be as bad off as decompensated patients with none.
From the Journals
AGA Clinical Care Pathway: Screening, diagnosis, and treatment of NAFLD and NASH
The authors recommended a four-step screening process for NAFLD/NASH based on available literature and clinical experience.
Conference Coverage
Alcohol-related liver disease severity increased during COVID-19 pandemic
Increased alcohol sales and disrupted services may have led to worse clinical outcomes.